A quarter of people with HCV initially refused access to sofosbuvir/lepidasvir, says US study, but ...
A quarter of people with HCV initially refused access to sofosbuvir/lepidasvir, says US study, but ...
- Insurers deny almost a quarter of requests for sofosbuvir/lepidasvir (Harvoni) to treat people with chronic hepatitis C virus (HCV) infection, investigators from Yale Liver Center report in PLoS One. However, most of those who were initially refused subsequently gained access after appeal.
- Insurers deny almost a quarter of requests for sofosbuvir/lepidasvir (Harvoni) to treat people with chronic hepatitis C virus (HCV) infection, investigators from Yale Liver Center report in PLoS One. However, most of those who were initially refused subsequently gained access after appeal.